Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline Review, H2 2020’, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ebolavirus Infections (Ebola Hemorrhagic Fever) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Ebolavirus Infections (Ebola Hemorrhagic Fever)

– The report reviews pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Ebolavirus Infections (Ebola Hemorrhagic Fever) therapeutics and enlists all their major and minor projects

– The report assesses Ebolavirus Infections (Ebola Hemorrhagic Fever) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Ebolavirus Infections (Ebola Hemorrhagic Fever) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abivax SA

AIkido Pharma Inc

AIM ImmunoTech Inc

Akshaya Bio Inc

AnGes Inc

ANP Technologies Inc

AntoXa Corp

Arisan Therapeutics Inc

Atreca Inc

Avipero Ltd

Beijing Mabworks Biotech Co Ltd

Bharat Biotech Ltd

BioComo Inc

BioCryst Pharmaceuticals Inc

BioFactura Inc

Biotron Ltd

Celdara Medical LLC

Chicago Biosolutions Inc

Cocrystal Pharma Inc

Collaborations Pharmaceuticals Inc

Eisai Co Ltd

Emergent BioSolutions Inc

Emergex Vaccines Ltd

Etubics Corp

Fab’entech SA

Fibreu Ltd

Flow Pharma Inc

Fox Chase Chemical Diversity Center Inc

Galactica Biotech Ltd

Gamaleya Federal Research Center of Epidemiology and Microbiology

GeoVax Labs Inc

Gilead Sciences Inc

Global BioLife Inc Ltd

Greffex Inc

H&P Labs Inc

Humabs BioMed SA

IDBiologics Inc

Immunomodulation Inc

Inovio Pharmaceuticals Inc

Integral Molecular Inc

Integrated BioTherapeutics Inc

IntelliStem Technologies Inc

Johnson & Johnson

Mapp Biopharmaceutical Inc

Merck & Co Inc

Microbiotix Inc

Micropharm Ltd

Novavax Inc

Oita University Institute of Advanced Medicine Inc

OncXerna Therapeutics Inc

Orgenesis Inc

Ostrich Pharma USA Inc

OyaGen Inc

Palisades Therapeutics

PanThera Biopharma LLC

Phelix Therapeutics LLC

Phoenix Biotechnology Inc

Profectus BioSciences Inc

Public Health Vaccines LLC

Regeneron Pharmaceuticals Inc

Riboscience LLC

Ridgeback Biotherapeutics LP

Rodos BioTarget GmbH

SAB Biotherapeutics Inc

Secarna Pharmaceuticals GmbH & Co. KG

Selva Therapeutics Inc

Soligenix Inc

Tiba Biotech LLC

Vaccibody AS

Vaxeal Holding SA

XBiotech Inc

Xenothera SAS

Yaso Therapeutics Inc

Yisheng Biopharma Co Ltd

Zalgen Labs LLC

Table of Contents

Table of Contents

Introduction

Ebolavirus Infections - Overview

Ebolavirus Infections - Therapeutics Development

Ebolavirus Infections - Therapeutics Assessment

Ebolavirus Infections - Companies Involved in Therapeutics Development

Ebolavirus Infections - Drug Profiles

Ebolavirus Infections - Dormant Projects

Ebolavirus Infections - Discontinued Products

Ebolavirus Infections - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Universities/Institutes, H2 2020

Number of Products by Stage and Target, H2 2020

Number of Products by Stage and Mechanism of Action, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Abivax SA, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by AIkido Pharma Inc, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by AIM ImmunoTech Inc, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Akshaya Bio Inc, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by AnGes Inc, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by ANP Technologies Inc, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by AntoXa Corp, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Arisan Therapeutics Inc, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Atreca Inc, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Avipero Ltd, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Beijing Mabworks Biotech Co Ltd, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Bharat Biotech Ltd, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by BioComo Inc, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by BioCryst Pharmaceuticals Inc, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by BioFactura Inc, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects, H2 2020

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), H2 2020

Number of Products under Development by Companies, H2 2020

Number of Products under Development by Universities/Institutes, H2 2020

Number of Products by Top 10 Targets, H2 2020

Number of Products by Stage and Top 10 Targets, H2 2020

Number of Products by Top 10 Mechanism of Actions, H2 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020

Number of Products by Top 10 Routes of Administration, H2 2020

Number of Products by Stage and Top 10 Routes of Administration, H2 2020

Number of Products by Top 10 Molecule Types, H2 2020

Number of Products by Stage and Top 10 Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports